| Name | Title | Contact Details |
|---|
EAG Life Sciences is a Maryland Heights, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AutoCruitment is a metrics-driven ecosystem of patient recruitment and engagement solutions, digitizing and revolutionizing the end-to-end patient and client experience. Our multifaceted approach utilizes sophisticated algorithms, advanced automation, and over 1,500 direct-to-patient online channels to find, screen, and automatically refer highly qualified patients with a greater chance of randomization success. The results are higher enrollment and greater patient engagement, accelerating timelines and exceeding milestones at every phase of clinical research. The AutoCruitment Difference: •Targeted: The AutoCruitment platform`s proprietary algorithms and innovative approach help precisely target your ideal patient population, reaching over 247 million patients to date •Experienced: AutoCruitment has completed over 578 studies and has a continuously learning and growing database of over 10 million patients •Technology-Enabled: The AutoCruitment platform utilizes advanced online screeners to simultaneously screen for multiple studies and provide customized cohort volumes based on your project`s needs •Volume- and Quality-Focused: The far-reaching power of the AutoCruitment platform and our direct-to-patient methodology excels at attracting and retaining optimal volumes of highly qualified patients •Transparent: The AutoCruitment portal and its robust reporting capabilities enable complete and real-time transparency from the very beginning •Metrics-Driven: Our patient recruitment scientists work in complete collaboration with your study teams and research sites to optimize the program and increase randomization by an average of 97% per month AutoCruitment delivers something different. Our comprehensive ecosystem of scalable solutions offers a 3-day startup time and swiftly removes the recruitment barrier for biotech innovations and pharmaceutical research, shortening timelines and trimming budgets for a quicker, smoother path to market.
Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density. Tricida has successfully completed all of the clinical trials that it planned to complete prior to submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), including a successful 135-subject, Phase 1/2 clinical trial (TRCA-101), a successful 217-subject, pivotal Phase 3 clinical trial (TRCA-301), and a successful 196-subject, Phase 3 extension trial (TRCA-301E). We plan to submit an NDA, in the second half of 2019, seeking approval of TRC101 through the FDA`s Accelerated Approval Program. Tricida was founded in August 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases. Tricida`s shared culture of teamwork, camaraderie and empowerment is evident in the dedication and focus our team demonstrates, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD, and bringing critically needed new therapies to patients.
Reset Therapeutics is a biopharmaceutical company formed to discover, develop and commercialize new therapeutics that modulate the circadian system, the body`s network of internal molecular clocks. The circadian system synchronizes behavioral and physiological processes, including sleep, metabolism, feeding, blood pressure and hormone secretion with the environmental cycles of light, activity and nutrient status. Disruption of normal circadian rhythms is associated with many diseases, including central nervous system, cardiovascular and metabolic disorders, immune system dysfunction and cancer. Novel therapies that reset the body’s biological clocks have the potential to benefit very large and diverse patient populations
At Organon, we envision a better and healthier every day for every woman. The diversity of our business provides a sustainable engine of growth so we can identify and invest in solutions for women. Our mission is to deliver impactful medicines and solutions for a healthier every day. We believe the journey to improve women`s health is critical to achieving a healthier world. We are united in our drive to better support the health of women within our company and around the globe. Together, we work toward our goal of finding solutions for the healthcare issues that matter most to her, today and every day.